

For Researchers

Overview of researcher access to patient-level data

Taiho Group (Taiho) provides a platform for accepting researchers' requests for sharing anonymized, patient-level, analyzable datasets from articles published in peer-reviewed journals about the primary results from Taiho-sponsored interventional clinical trials in patients in which the medicine and the indication has received marketing approval from regulatory authorities in the United States, the European Union, and/or Japan on or after January 15, 2018. The shared data will be available from 12 months to 48 months after the article's publication.

Taiho will not share patient-level data if: 1) risks for identification of patients are substantial or anonymization is difficult to achieve (e.g., small studies); 2) clinical data collected were subject to legal, contractual, or consent provisions that prohibit or do not allow data sharing with third parties; 3) data sharing is not technically feasible (e.g., data and associated documents are not available in English); or 4) it is necessary to restrict information to protect commercially confidential information and intellectual property rights.

Access to the clinical trial data is contingent upon approval of a proposed study protocol by an independent review panel and the execution of a data-sharing agreement with the researcher.

Inquiries for data sharing may be sent to the following e-mail address:

th-datasharing@taiho.co.jp.

September 2019